➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Merck
Medtronic
Mallinckrodt
McKesson

Last Updated: January 27, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Staurosporine

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Staurosporine?

Staurosporine is an investigational drug.

There have been 29 clinical trials for Staurosporine. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2017.

The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, Acute, and Leukemia, Myeloid. The leading clinical trial sponsors are National Cancer Institute (NCI), University Health Network, Toronto, and Memorial Sloan Kettering Cancer Center.

There is one US patent protecting this investigational drug and fourteen international patents.

Recent Clinical Trials for Staurosporine
TitleSponsorPhase
Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeNational Cancer Institute (NCI)Phase 2/Phase 3
Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-TransplantNational Cancer Institute (NCI)Phase 2
Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-TransplantStanford UniversityPhase 2

See all Staurosporine clinical trials

Clinical Trial Summary for Staurosporine

Top disease conditions for Staurosporine
Top clinical trial sponsors for Staurosporine

See all Staurosporine clinical trials

US Patents for Staurosporine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Staurosporine   Start Trial Substituted indole Mcl-1 inhibitors Vanderbilt University (Nashville, TN)   Start Trial
Staurosporine   Start Trial Compositions and methods for inhibiting intimal hyperplasia   Start Trial
Staurosporine   Start Trial Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: III Frequency Therapeutics, Inc. (Woburn, MA)   Start Trial
Staurosporine   Start Trial Efficient transport into white blood cells Xigen Inflammation Ltd. (Limassol, CY)   Start Trial
Staurosporine   Start Trial Organic compositions to treat beta-catenin-related diseases Arrowhead Pharmaceuticals, Inc. (Pasadena, CA)   Start Trial
Staurosporine   Start Trial SC-.beta. cells and compositions and methods for generating the same President and Fellows of Harvard College (Boston, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Staurosporine

Drugname Country Document Number Estimated Expiration Related US Patent
Staurosporine Canada CA2922341 2033-08-28   Start Trial
Staurosporine European Patent Office EP3038618 2033-08-28   Start Trial
Staurosporine World Intellectual Property Organization (WIPO) WO2015031608 2033-08-28   Start Trial
Staurosporine Australia AU2009331921 2028-12-22   Start Trial
Staurosporine Australia AU2009331922 2028-12-22   Start Trial
Staurosporine Canada CA2738951 2028-12-22   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Merck
Medtronic
Mallinckrodt
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.